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Background & AimsNonalcoholic steatohepatitis (NASH) is a prevalent liver disease
associated with increased morbidity and mortality. Ursodeoxycholic acid (UDCA)
may have antioxidant, anti-inflammatory, and antifibrotic properties and may reduce
liver injury in NASH. To date, no studies have assessed the efficacy and safety of
high-dose UDCA (HD-UDCA) in patients with NASH. Methods We conducted a 12-
month, randomized, double-blind, placebo-controlled multicenter trial to evaluate the
efficacy and safety of HD-UDCA (28–35 mg/kg per day) in 126 patients with biopsy-
proven NASH and elevated alanine aminotransferase (ALT) levels. The primary study
end point was reduction in ALT levels from baseline in patients treated with HD-
UDCA compared with placebo. Secondary study end points were the proportion of
patients with ALT normalization, relative reduction in the scores of serum markers of
fibrosis and hepatic inflammation, and safety and tolerability. Results HD-UDCA
significantly reduced mean ALT levels −28.3% from baseline after 12 months
compared with −1.6% with placebo (p <0.001). At the end of the trial, ALT levels
normalized (⩽35 IU/L) in 24.5% of patients treated with HD-UDCA and in 4.8% of
patients who received placebo (p = 0.003). Both results were not accounted for by
changes in weight during the trial. HD-UDCA significantly reduced the FibroTest®
serum fibrosis marker (p <0.001) compared with placebo. HD-UDCA also
significantly improved markers of glycemic control and insulin resistance. There
were no safety issues in this population. Conclusions Treatment with HD-UDCA was
safe, improved aminotransferase levels, serum fibrosis markers, and selected






























Publié sur Okina (http://okina.univ-angers.fr)
